Literature DB >> 11914546

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

Rosa Teijeiro1, Ramón Rios, José A Costoya, Ramón Castro, José L Bello, Jesús Devesa, Victor M Arce.   

Abstract

The ability of both somatostatin (SS) and its stable analogues to inhibit cell growth depends on the stimulation of specific membrane receptors (SSTR1-5), which belong to the G protein-coupled receptor family. Accumulating evidence suggests that the SSTR2 plays a major role in mediating cell cycle arrest, and it is also clear that SHP-1, a cytoplasmic phosphotyrosine phosphatase (PTP), is an essential component of the SSTR2-mediated cytostatic effect. In contrast, the possibility that SSTR2 activation may also lead to increased apoptosis is still beyond debate, despite SHP-1 activation is also able to promote cell death in several cell types. In the present work we have investigated the ability of SSTR2 to induce apoptosis in HL-60 cells. We have found that HL-60 cells uniquely express the SSTR2 subtype, and that stimulation of SSTR2 with the SS analogue SMS 201-995 results in an increased cell death. In all, these findings demonstrate that activation of SSTR2 promotes apoptosis in HL-60 cells. Moreover, in contrast with the proapoptotic mechanism previously reported for SSTR3, cell death induced by activation of SSTR2 is independent from accumulation of p53. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914546     DOI: 10.1159/000047824

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  19 in total

Review 1.  Cation channels, cell volume and the death of an erythrocyte.

Authors:  Florian Lang; Karl S Lang; Thomas Wieder; Svetlana Myssina; Christina Birka; Philipp A Lang; Stephanie Kaiser; Daniela Kempe; Christophe Duranton; Stephan M Huber
Journal:  Pflugers Arch       Date:  2003-08-07       Impact factor: 3.657

2.  Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

Authors:  A P Casarini; E M Pinto; R S Jallad; R R Giorgi; D Giannella-Neto; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

Review 4.  Treatment of pituitary tumors: somatostatin.

Authors:  Maria A Tichomirowa; Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

5.  Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.

Authors:  Jing-Hua Wang; Quan-Tai Xing; Meng-Biao Yuan
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

6.  Antiproliferative and proapoptotic effects of somatostatin on activated hepatic stellate cells.

Authors:  Qin Pan; Ding-Guo Li; Han-Ming Lu; Liang-Yong Lu; Yu-Qin Wang; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

7.  Upregulated expression of SSTR1 is involved in neuronal apoptosis and is coupled to the reduction of bcl-2 following intracerebral hemorrhage in adult rats.

Authors:  Damin Yuan; Jianhong Shen; Yaohua Yan; Xinmin Wu; Aihong Li; Aisong Guo; Yuanyuan Wu; Chengwei Duan; Jiabing Shen; Cuiying Tang; Dongmei Zhang; Yuhong Ji
Journal:  Cell Mol Neurobiol       Date:  2014-07-18       Impact factor: 5.046

8.  Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.

Authors:  Guida Maria Portela-Gomes; Mats Stridsberg; Lars Grimelius; Otto Rorstad; Eva Tiensuu Janson
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

9.  Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

Authors:  D Dimitroulopoulos; D Xinopoulos; K Tsamakidis; A Zisimopoulos; E Andriotis; D Panagiotakos; A Fotopoulou; C Chrysohoou; A Bazinis; D Daskalopoulou; E Paraskevas
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

10.  Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study.

Authors:  Maximilian Schöniger-Hekele; Joachim Kettenbach; Markus Peck-Radosavljevic; Christian Müller
Journal:  J Exp Clin Cancer Res       Date:  2009-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.